Changing Diabetes in Children: A public-private partnership delivering diabetes care to children in low- and middle-income countries Custom Case Solution & Analysis

Strategic Gaps

The Changing Diabetes in Children initiative exhibits three primary structural vulnerabilities that threaten its long-term viability and impact.

• Dependency on Vertical Integration: The model relies heavily on the goodwill and operational stability of local ministries of health. In environments where administrative continuity is fragile, the lack of an independent, non-governmental distribution contingency creates a significant single-point-of-failure risk.
• Absence of Value-Based Pricing Mechanisms: By focusing predominantly on donation-led supply, the initiative lacks a defined roadmap for price discovery or transition to commercial sustainability. It creates a ceiling on market development rather than an entry ramp for the broader Novo Nordisk portfolio.
• Data-to-Outcome Asymmetry: While registries track patient participation, there is a disconnect between clinical data capture and systemic policy influence. The current model records health status but fails to mandate the procurement reforms required to institutionalize pediatric diabetes care into national health budgets.

Strategic Dilemmas

The leadership faces three fundamental trade-offs that require immediate resolution to ensure program endurance.

In summary, the strategic challenge is moving from a humanitarian gesture to an integrated component of national health architecture. Without a clear exit strategy for the donor-dependent phase, the program risks becoming a permanent liability rather than an engine for market transformation.

Execution Roadmap: CDiC Transformation Phase

This implementation plan transitions the Changing Diabetes in Children initiative from a humanitarian delivery vehicle to a sustainable market-integrated system. The roadmap is categorized into three mutually exclusive and collectively exhaustive phases.

Phase 1: Resilience and Continuity (Months 1-12)

Objective: Eliminate single-point-of-failure risks through infrastructure diversification.

• Logistics Decentralization: Initiate pilot programs with regional private-sector distributors to create a parallel supply chain, reducing total reliance on government-only pathways.
• Procurement Advocacy: Formalize data-sharing agreements with Ministries of Health to turn existing patient registries into evidence-based advocacy tools for national budget inclusion.
• Governance Realignments: Establish local health advisory boards to insulate program operations from administrative turnover within public health departments.

Phase 2: Market Integration (Months 13-36)

Objective: Shift the model from donation-led supply to tiered pricing and local resilience.

Phase 3: Institutionalization and Commercial Maturity (Months 37+)

Objective: Finalize the handover to national systems and integrate the program into the broader Novo Nordisk market strategy.

• Full System Integration: National health budgets fully absorb the procurement of insulin and supplies, utilizing established private-sector logistics chains.
• Commercial Portfolio Alignment: Leverage the footprint created by CDiC to introduce secondary products and diagnostic services under a unified regional commercial strategy.
• CSR to ESG Shift: Reclassify the initiative from a corporate social responsibility cost center to a foundational element of regional ESG compliance and market access.

Strategic Oversight and Risk Mitigation

To ensure success, the steering committee must maintain a separation between humanitarian delivery and commercial development teams. This structure mitigates the conflict of interest inherent in the Donation vs. Marketization dilemma while ensuring clear accountability for quarterly milestones.

Executive Audit: CDiC Transformation Roadmap

As a reviewer, I find this roadmap structurally ambitious but operationally precarious. You have conflated market access strategy with humanitarian scaling, creating significant enterprise risk. Below is the critical assessment of logical gaps and strategic dilemmas.

Critical Logical Flaws and Blind Spots

• Assumption of Government Compliance: The plan assumes Ministries of Health will absorb procurement costs after Phase 2. This ignores the reality of fiscal constraints in developing markets where shifting from a free donor-subsidized supply to a national budget line item often triggers political rejection or funding gridlock.
• Logistics Paradox: Phase 1 mandates decentralization to private distributors. However, these partners typically require economies of scale that do not exist in underserved pediatric markets. The roadmap fails to define who covers the unit-cost delta during this transition.
• Conflict of Interest Mitigation: You suggest a separation between humanitarian and commercial teams. In practice, this creates an operational silo where commercial teams likely cannibalize humanitarian efforts, or humanitarian teams become a drag on commercial velocity. You have not defined the governance mechanism to resolve this friction.

Core Strategic Dilemmas

Reviewer Summary

The transition from CSR to ESG is the most significant leap in your roadmap. You are shifting from a cost-sink to a market-building investment. Unless you provide a clear exit strategy for the donation components that does not alienate current government partners, the Phase 3 institutionalization goals remain speculative. You must quantify the cost of this transition relative to projected regional lifetime value (LTV) to justify this to the board.

Operational Execution Roadmap: CDiC Transition Strategy

To address the identified risks of fiscal instability and operational friction, the following roadmap establishes a tiered transition model. This strategy prioritizes long-term viability by bridging the gap between donor-subsidized entry and sustainable market integration.

Phase 1: Transitional Infrastructure Stabilization (Months 1-6)

Focus: Establishing the governance framework to mitigate supply chain bifurcation and resource cannibalization.

• Unified Governance Office: Establish a dual-reporting oversight committee to synchronize humanitarian and commercial objectives, preventing resource silos.
• Unit Cost Subsidy Bridge: Launch a multi-stakeholder venture fund to cover the unit-cost delta for private distributors, ensuring cold-chain viability until economies of scale are achieved.

Phase 2: Tiered Integration and Fiscal Proofing (Months 7-18)

Focus: Institutionalizing the program while preparing for full state absorption of procurement costs.

• Outcome-Based Contracting: Implement pilot agreements with Ministries of Health that utilize performance-linked outcomes rather than immediate budget line transfers.
• Data Resilience Protocol: Decentralize clinical guideline data management to a regional cloud architecture, insulating operational continuity from localized political volatility.

Phase 3: Scalable Market Maturity (Months 19+)

Focus: Transitioning to an ESG-compliant commercial model with high regional LTV.

• Exit Strategy Execution: Gradual phase-out of donation-led supply in favor of a hybrid procurement model that sustains access for the bottom-of-pyramid demographics.
• Sustainability Verification: Annual audits demonstrating market-building impact, providing the board with clear quantitative evidence of LTV growth versus the initial CSR cost-sink.

Strategic Implementation Matrix

Note: This roadmap shifts the narrative from donor dependency to resilient market participation. Future reporting will focus on the quantitative tracking of LTV milestones to satisfy institutional investor requirements.

Partner Review: CDiC Transition Strategy Assessment

The proposed roadmap reads as a sanitized consultant deck. While the language is polished, it lacks the tactical rigor required to survive a skeptical board review. You are betting on state cooperation and market forces in environments that are historically allergic to both.

Verdict

Insufficient. The plan suffers from an institutional optimism bias. It assumes that governance frameworks can resolve structural political instability and that commercial market dynamics will naturally fill the void left by donor subsidies without catastrophic service degradation. It fails the So-What test by prioritizing process over cash-flow protection.

Required Adjustments

• The So-What Test: Define the failure threshold. At what point does the Unit Cost Subsidy Bridge become a sunk-cost trap? You must establish a clear circuit-breaker clause for private distributors who fail to achieve scale within the 18-month window.
• Trade-off Recognition: Explicitly address the friction between Humanitarian mandate (access at all costs) and Commercial viability (profit-maximizing supply chains). You currently assume these can be synchronized; they often cannot. Identify which KPI takes precedence when the two are in direct conflict.
• MECE Violations: The Transition Pillars in your matrix are not mutually exclusive. Fiscal Absorption is inextricably linked to Operational Friction. Segregating them creates artificial silos that mirror the very fragmentation you claim to be resolving. Restructure to focus on (1) Capital Risk, (2) Political Agency, and (3) Operational Velocity.

Contrarian View

The strategy is fundamentally misguided because it attempts to impose a Western, market-based maturity curve on a non-market environment. Instead of trying to transition the CDiC into a commercial entity, you should advocate for permanent donor-backed utility status. By forcing commercialization, you increase complexity and cost, effectively inviting private sector rent-seeking behavior that will ultimately destroy the program efficiency you intend to protect.

Executive Summary: Changing Diabetes in Children (CDiC) Initiative

This case study examines the efficacy and operational framework of the Changing Diabetes in Children program, a multi-stakeholder public-private partnership (PPP) spearheaded by Novo Nordisk. The initiative addresses the critical gap in Type 1 diabetes care for children within resource-constrained environments by integrating supply chain management, healthcare provider training, and patient registry development.

Core Strategic Pillars

• Supply Chain Optimization: Ensuring consistent access to insulin and diagnostic supplies in low- and middle-income countries (LMICs).
• Capacity Building: Implementing rigorous training programs for medical professionals to improve diagnostic accuracy and long-term disease management.
• Patient Empowerment: Establishing local registries and educational initiatives to increase adherence and reduce mortality rates among pediatric patients.

Economic and Operational Framework

Critical Success Factors

The program leverages a model of shared value, aligning Novo Nordisk global corporate social responsibility goals with the public health mandates of host nations. Key success metrics revolve around reducing diagnostic delays and improving glycemic control among participating children. The partnership model overcomes traditional barriers to entry in LMIC health markets by utilizing local health ministries to distribute specialized goods, thereby reducing the overhead of independent delivery networks.

Operational Challenges and Considerations

The case highlights the inherent volatility of operating within fragile health systems. Challenges include the need for constant monitoring to prevent supply leakage, the requirement for cold chain infrastructure in remote areas, and the necessity of ensuring that healthcare infrastructure remains robust enough to manage chronic care beyond the initial donation period. Sustaining the initiative requires transitioning from a donor-dependent model to one that integrates seamlessly into national health budgets over the long term.